The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features a real-time scorecard of the Q1 earnings season and freshly updated research reports on ...

With a market cap of $775.6 billion, Eli Lilly and Company (LLY) is a global biopharmaceutical leader with leading products ...

The stock fell after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant ...

We recently published a list of the 13 Best American Dividend Stocks to Buy According to Analysts. In this article, we are ...

A new pill designed by Eli Lilly to help with weight loss and blood sugar control is showing promise in early studies.

Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Eli Lilly's stock leapt 14.5% on Friday, soaring past $840 with a trading volume explosion of 217%. Analysts from Morgan Stanley, Wells Fargo, and Goldman Sachs issued updated buy ratings, nudging ...

Eli Lilly gains ground with Orforglipron’s success, showing growth potential and risks from momentum and tariffs. Read why ...

Savvy pharma-stock investors know that an oral GLP-1 drug from Novo Nordisk called Rybelsus has been on the market as a ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly & Co.'s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...